Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced it has signed a Letter of Intent to merge with Algorithm Sciences, Inc. (“Algorithm”) a company focused on Pulmonary Arterial Hypertension (PAH). The combined company will be named Algorithm Sciences, Inc. and be led by experienced biopharma executives, including Mike Tilton as CEO, David Cavalier as CFO and Anthony Zook, Algorithm’s current chairman of the board, who will be nominated as chairman of the combined company’s board of directors. Algorithm will become the majority holders of Hoth’s outstanding stock by way of a merger.
Read the full article: Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge //
Source: https://www.prnewswire.com/news-releases/hoth-therapeutics-and-algorithm-sciences-execute-letter-of-intent-to-merge-301807721.html